Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 5, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Moderna’s mRNA–1273 granted emergency use authorization by FDA

AIIMS Bhopal Life Science Junior Research Fellow Job Opening

AIIMS Delhi Genetic Diagnoses SRF Recruitment | Applications Invited

Moderna’s mRNA–1273 granted emergency use authorization by FDA
  • BiotechToday
  • World

Moderna’s mRNA–1273 granted emergency use authorization by FDA

bioxone December 28, 2020December 28, 2020

Prama Ghosh, Amity University Kolkata

The Food and Drug Administration announced granted emergency use authorization to Moderna’s mRNA–1273, it’s COVID-19 vaccine for use in individuals 18 and older Friday night, the second vaccination against the coronavirus in the United States one week after the agency authorized a similar vaccine from Pfizer and BioNTech.

Moderna’s vaccine is more than 94% effective just like Pfizer’s vaccine which is already in use. mRNA–1273 can be stored and transported at a temperature maintained by a standard refrigerator for 30 days. It requires two doses given 28 days apart, unlike 21 days for the Pfizer shot. The mRNA technology used by both Moderna and Pfizer vaccines provides a recipe to the body. To make the spike proteins found on the outside of the coronavirus, which triggers an immune response.

Under Operation Warp Speed two-hundred million doses of Moderna’s vaccine have already been ordered by the US government. The government also has an option to purchase up to 300 million additional doses. Post authorization of both Pfizer and Moderna’s vaccines, around 20 million people are expected to be vaccinated by the end of the year. FDA Commissioner Stephen M. Hahn, M.D. has taken another crucial step. Making two vaccines available for the prevention of COVID-19. On average 216,000 new cases are being recorded in the U.S per day with deaths reaching as high as 3,600 per day. Moderna plans its future trials which include continued studies in children with a closer look at possible serious reactions, including Bell’s palsy.

Also read: Triple-negative breast cancer and PARP inhibitor to overcome immunosuppressive macrophages

References:

1) https://www.wcvb.com/article/moderna-covid-vaccine-emergency-use-authorization-december-18-2020/35016735

2) https://spectrumnews1.com/ky/northern-ky/news/2020/12/19/moderna-covid-vaccine-fda-emergency-use

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Clinical trial corona virus COVID – 19 COVID – 19 vaccines emergency authorization FDA mRNA – 1273 vaccination vaccine doses

2 thoughts on “Moderna’s mRNA–1273 granted emergency use authorization by FDA”

  1. Pingback: A stronger COVID-19 mutant found - BioXone
  2. Pingback: International Clinical Trials Day, 2021 - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

AIIMS Delhi Genetic Diagnoses SRF Recruitment | Applications Invited

bioxone December 28, 2020

-Shristi Sharma, Team bioXone AIIMS Delhi SRF Recruitment – Applications Invited. Senior Research Fellow Jobs for Genomics/ Bioinformatics/life sciences applicants. Interested and eligible applicants can check out all of the details on the same below: All India Institute of Medical Sciences Ansari Nagar, New Delhi – 110029 Name of the Post: Senior Project Associate No. […]

Related Post

  • BiotechToday
  • World

Researches discover how more than a hundred genes assist cancer in evasion of the immune system

bioxone September 26, 2020September 26, 2020

Sayak Banerjee, Amity University Kolkata Immunotherapy, although being a formidable cancer treatment, produces durable responses for a few tumor types only. Lately, scientists have identified 182 genes that enable the cancer cells to evade death by the immune system. They carried out genome-wide CRISPR screens across a group of genetically varying mouse cancer cell lines, […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

In pursuit of a prime drug for Pemphigus Vulgaris

bioxone June 21, 2021June 21, 2021

Monika R, PSG College of Technology, Coimbatore Derived from the Greek word pemphix, pemphigus means “vesicle” or “blister”. There are many different types of pemphigus, all involving vesicle formation at some stage, but Pemphigus Vulgaris (autoimmune disease) is the most common of all and is characterized by blistering and erosions of mucous membranes and skin.  […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Gene therapy clinical trials for rare Angelman syndrome put on hold

bioxone November 7, 2020November 6, 2020

Surupa Chakraborty, Amity University Kolkata A new gene therapy clinical trial for treating Angelman syndrome has been put to hold after two candidates temporarily lost their ability to walk. GTX102, the drug used in the clinical trial was developed by a California-based biopharmaceutical company Ultragenyx, in collaboration with GeneTx, a Florida-based biotech startup. The trial […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy